TCGA-J2-A4AD-01A-11R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.230
- SPERMATOGENESIS+0.180
- MYOGENESIS+0.170
- COAGULATION+0.100
- BILE_ACID_METABOLISM+0.090
- GLYCOLYSIS+0.010
- FATTY_ACID_METABOLISM+0.000
- UV_RESPONSE_DN-0.020
- NOTCH_SIGNALING-0.030
- PROTEIN_SECRETION-0.030
Top 10 suppressed
- MYC_TARGETS_V2-0.590
- MYC_TARGETS_V1-0.550
- OXIDATIVE_PHOSPHORYLATION-0.510
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.470
- INTERFERON_ALPHA_RESPONSE-0.460
- INFLAMMATORY_RESPONSE-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- MTORC1_SIGNALING-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG491 | — | — | 0.885 |
| 2 | BS_063ERW0R | pilocytic astrocytoma | — | 0.882 |
| 3 | TCGA-MN-A4N1-01A-11R-A24X-07 | — | cohortA1 | 0.882 |
| 4 | SRR1442885 | GTEX | — | 0.880 |
| 5 | SRR821581 | GTEX | — | 0.879 |
| 6 | SRR1466069 | GTEX | — | 0.879 |
| 7 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.876 |
| 8 | C3N-03921 | — | cohortA1 | 0.870 |
| 9 | BS_C80S5N37 | Ependymoma NOS | — | 0.869 |
| 10 | TCGA-97-7937-01A-11R-2170-07 | — | cohortA1 | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |